SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN
SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started